JosephPHorriganMDFAACAP
Psychiatry • Research Triangle Park, NCChild & Adolescent Psychiatry
Physician
Dr. Horrigan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Five Moore Drive
Research Triangle Park, NC 27709Phone+1 919-483-7942Fax+1 919-483-8302
Education & Training
University of North Carolina HospitalsFellowship, Child and Adolescent Psychiatry, 1991 - 1994- University of North Carolina HospitalsResidency, Psychiatry, 1988 - 1991
University of Rochester School of Medicine and DentistryClass of 1988
Certifications & Licensure
CA State Medical License 1998 - 2026
ME State Medical License 2021 - 2026
MA State Medical License 1994 - 2025
NC State Medical License 1990 - 2025
RI State Medical License 1999 - 1999- American Board of Psychiatry and Neurology Psychiatry
- American Board of Psychiatry and Neurology Child & Adolescent Psychiatry
Clinical Trials
- Study of NNZ-2566 in Patients With Traumatic Brain Injury Start of enrollment: 2010 Apr 01
- Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC Start of enrollment: 2013 Feb 01
- A Safety Study of NNZ-2566 in Patients With Rett Syndrome Start of enrollment: 2013 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsDevelopment of trofinetide for the treatment of Rett syndrome: from bench to bedside.Melissa Kennedy, Larry Glass, Daniel G Glaze, Steve Kaminsky, Alan K Percy
Frontiers in Pharmacology. 2023-01-01 - 38 citationsA Phase 2 Study of AMO-02 (Tideglusib) in Congenital and Childhood-Onset Myotonic Dystrophy Type 1 (DM1)Joseph P. Horrigan, Tiago Gomes, Mike Snape, Nikoletta Nikolenko, Alison McMorn
Pediatric Neurology. 2020-11-01 - 28 citationsA Phase II Randomized Clinical Trial of the Safety and Efficacy of Intravenous Umbilical Cord Blood Infusion for Treatment of Children with Autism Spectrum Disorder.Geraldine Dawson, Jessica Sun, J.H. Baker, Kimberly L. H. Carpenter, Scott N. Compton
The Journal of Pediatrics. 2020-07-01
Press Mentions
AMO Pharma Announces Expansion of Pivotal REACH-CDM Study in Congenital Myotonic DystrophyDecember 22nd, 2021- AMO Pharma Announces Activation of Additional Clinical Trial Sites for Pivotal REACH-CDM Study in Congenital Myotonic DystrophyMay 17th, 2021
- AMO Pharma to Participate in Myotonic Dystrophy Foundation "Meet the DM Drug Developers" Program on March 5, 2021March 3rd, 2021
- Join now to see all
Professional Memberships
- Fellow
- Fellow
- Member
- Member
- International Society for Autism ResearchMember
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
